11:11:45 EDT Sun 12 May 2024
Enter Symbol
or Name
USA
CA



Avivagen Inc (2)
Symbol VIV
Shares Issued 77,694,700
Close 2023-07-24 C$ 0.015
Market Cap C$ 1,165,421
Recent Sedar Documents

Avivagen receives orders for 1.1 tonnes of OxC-beta

2023-07-24 09:58 ET - News Release

Mr. Kym Anthony reports

AVIVAGEN ANNOUNCES NEW ORDERS FOR 1.1 TONNES OF OXC-BETA(TM) LIVESTOCK PRODUCT

Avivagen Inc. has received two orders for OxC-beta. One order, for 500 kilograms, is with a new customer for use within the sow market, while the second order, for 600 kg, involves 100 kg for immediate delivery and an additional 100 kg per month over the next five months.

About OxC-beta technology and OxC-beta livestock

Avivagen's OxC-beta technology is derived from Avivagen discoveries about beta-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia.

Avivagen's OxC-beta livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.